TY - JOUR
T1 - Assessing the impact of jail-initiated medication for opioid use disorder
T2 - A multisite analysis of the SOMATICS collaborative
AU - Lee, Joshua D.
AU - Goldfeld, Keith
AU - Schwartz, Robert P.
AU - McDonald, Ryan
AU - Xu, Yifan
AU - Chandler, Redonna
AU - Hallgren, Kevin
AU - Kelly, Sharon M.
AU - Mitchell, Shannon Gwinn
AU - Sharma, Anjalee
AU - Farabee, David
N1 - Publisher Copyright:
© 2024 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2024/6
Y1 - 2024/6
N2 - The objective of this study was to estimate the associations of jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) with opioid use disorder (OUD) at 6 months post-release. Three randomized trials (combined N = 330) were combined to assess whether MOUD (extended-release naltrexone or interim methadone) initiated prior to release from jail with or without PN would reduce the likelihood of a DSM-5 diagnosis of OUD 6 months post-release relative to enhanced treatment-as-usual (ETAU). Across the three studies, assignment to MOUD compared to ETAU was not associated with an OUD diagnosis at 6 months post-release (69% vs. 75%, respectively, OR = 0.67, 95% CI: 0.42 to 1.20). Similarly, PN compared to MOUD without PN was not associated with an OUD diagnosis (63% vs 77%, respectively, OR = 0.61, 95% CI: 0.27 to 1.53). Results underscore the need to further optimize the effectiveness of MOUD for patients initiating treatment in jail, beginning with an emphasis on post-release treatment adherence.
AB - The objective of this study was to estimate the associations of jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) with opioid use disorder (OUD) at 6 months post-release. Three randomized trials (combined N = 330) were combined to assess whether MOUD (extended-release naltrexone or interim methadone) initiated prior to release from jail with or without PN would reduce the likelihood of a DSM-5 diagnosis of OUD 6 months post-release relative to enhanced treatment-as-usual (ETAU). Across the three studies, assignment to MOUD compared to ETAU was not associated with an OUD diagnosis at 6 months post-release (69% vs. 75%, respectively, OR = 0.67, 95% CI: 0.42 to 1.20). Similarly, PN compared to MOUD without PN was not associated with an OUD diagnosis (63% vs 77%, respectively, OR = 0.61, 95% CI: 0.27 to 1.53). Results underscore the need to further optimize the effectiveness of MOUD for patients initiating treatment in jail, beginning with an emphasis on post-release treatment adherence.
UR - http://www.scopus.com/inward/record.url?scp=85196598508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196598508&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0305165
DO - 10.1371/journal.pone.0305165
M3 - Article
C2 - 38885220
AN - SCOPUS:85196598508
SN - 1932-6203
VL - 19
JO - PloS one
JF - PloS one
IS - 6
M1 - e0305165
ER -